First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

Smith, Ie; Pierga, Jy; Biganzoli, L; Cortés Funes, H; Thomssen, C; Pivot, X; Fabi, A; Xu, B; Stroyakovskiy, D; Franke, Fa; Kaufman, B; Mainwaring, P; Pienkowski, T; De Valk, B; Kwong, A; González Trujillo, Jl; Koza, I; Petrakova, K; Pereira, D; Pritchard, Ki; Adamo, Vincenzo